Genentech Asks FDA TO Hold Off Biogenerics Policy Paper
Genentech’s petition argues that it would be impossible for the FDA to release the plan or approve generic versions of its drugs without infringing on the company’s trade secrets.
"We draw the line at agency reference to or reliance on Genentech trade secret and confidential commercial data and information to approve a competitor's product,"...
Already a subscriber? Click here to login